Asphyxia Neonatorum Market

Market Overview:

The 7 major asphyxia neonatorum markets are expected to exhibit a CAGR of 10.2% during 2024-2034.

The asphyxia neonatorum market has been comprehensively analyzed in IMARC's new report titled "Asphyxia Neonatorum Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Asphyxia neonatorum refers to a critical condition in newborns where there is a significant lack of oxygen supply to their vital organs, leading to potential damage and life-threatening complications. This ailment can arise during the birthing process or shortly thereafter. The symptoms of the illness can vary in severity and may include pale or bluish skin color (cyanosis), weak or absent breathing, a low heart rate, poor muscle tone, and altered consciousness. Newborns suffering from severe asphyxia may exhibit more pronounced indications, such as seizures, difficulty feeding, and an overall lethargic state. The diagnosis of this ailment typically involves a clinical examination, monitoring vital signs, and evaluating the newborn's response to resuscitative efforts. Apgar scores, which assess appearance, pulse, grimace, activity, and respiration, are often used to quickly determine the newborn's overall condition and guide medical interventions. Additional diagnostic tests, such as blood gas analysis and brain imaging, may be conducted to detect the extent of oxygen deprivation and potential organ damage.

The increasing prevalence of umbilical cord complications that can restrict blood flow and oxygen supply is primarily driving the asphyxia neonatorum market. In addition to this, the inflating utilization of effective treatments, including assisted ventilation, oxygen therapy, and specialized neonatal care, to mitigate the immediate effects and prevent lasting harm is also creating a positive outlook for the market. Moreover, the widespread adoption of therapeutic hypothermia, a technique that involves cooling the newborn's body temperature to reduce potential brain damage caused by oxygen deprivation, is further bolstering the market growth. This approach holds promise for minimizing long-term neurological complications and enhancing the overall prognosis for infants suffering from the illness. Additionally, the rising application of pharmacological treatments, such as antioxidants and neuroprotective agents, given their potential to decrease cellular damage, is acting as another significant growth-inducing factor. Apart from this, the emerging popularity of evidence-based guidelines for immediate postnatal care, including practices like delayed cord clamping and skin-to-skin contact, is also augmenting the market growth. Furthermore, the escalating usage of stem cell therapy, which involves administering stem cells to stimulate tissue repair and regeneration in patients, is expected to drive the asphyxia neonatorum market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the asphyxia neonatorum market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for asphyxia neonatorum and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the asphyxia neonatorum market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the asphyxia neonatorum market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the asphyxia neonatorum market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current asphyxia neonatorum marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the asphyxia neonatorum market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the asphyxia neonatorum market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the asphyxia neonatorum market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of asphyxia neonatorum across the seven major markets?
• What is the number of prevalent cases (2018-2034) of asphyxia neonatorum by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of asphyxia neonatorum by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with asphyxia neonatorum across the seven major markets?
• What is the size of the asphyxia neonatorum patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of asphyxia neonatorum?
• What will be the growth rate of patients across the seven major markets?
   

Asphyxia Neonatorum: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for asphyxia neonatorum drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the asphyxia neonatorum market?
• What are the key regulatory events related to the asphyxia neonatorum market?
• What is the structure of clinical trial landscape by status related to the asphyxia neonatorum market?
• What is the structure of clinical trial landscape by phase related to the asphyxia neonatorum market?
• What is the structure of clinical trial landscape by route of administration related to the asphyxia neonatorum market?